Cardio Diagnostics more than doubles in value amid launch of heart disease blood test
Feb. 28, 2023 8:50 AM ETCardio Diagnostics Holdings, Inc. (CDIO)By: Anuron Mitra, SA News Editor2 Comments
- Shares of Cardio Diagnostics (NASDAQ:CDIO) on Tuesday have more than doubled in value in premarket trading, adding to a ~20% gain in the previous session.
- CDIO stock was up 143.8% to $3.12 ahead of the opening bell. On Monday, the stock had ended 20.3% higher at $1.33.
- Chicago, Ill.-based CDIO uses artificial intelligence (AI) to develop and commercialize clinical tests for the detection and prevention of cardiovascular disease.
- Today's premarket advance in CDIO stock comes amid the announcement of a launch of a blood test by the company for the early detection of coronary heart disease.
- The test, called PrecisionCHD, is the second clinical test built using Cardio Diagnostics’ (CDIO) proprietary AI-driven Integrated Epigenetic-Genetic Engine, the company said in a statement.
- The company also said it plans develop more tests for other cardiovascular diseases and associated conditions over the next two years.